Use of a Recombinant Cysteine Proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of Canine Visceral Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 8, Issue 3, 2014, Pages

  Ferreira, Josie Haydée Lima ^a,b   Silva, Lucilene dos Santos ^b   Longo Maugéri, Ieda Maria ^a   Katz, Simone ^a   Barbiéri, Clara Lúcia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; LEISHMANIA CHAGASI; MICROSCOPY; NONHUMAN; PARASITE LOAD; PROPIONIBACTERIUM ACNES; PROTEIN EXPRESSION; PROTEIN PURIFICATION; VISCERAL LEISHMANIASIS; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, PROTOZOAN; BRAZIL; CYSTEINE PROTEASES; CYTOKINES; DOG DISEASES; DOGS; IMMUNOTHERAPY; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MICE; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84897452011     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002729     Document Type: Article

References (52)

1. Alvar J, Vélez ID, Berne C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
2. WHO (2010) Control of leishmaniasis. Report of the Expert Commitee. World Health Organization. Tech Rep Ser 949: 1-186.
3. Arias JR, Monteiro PS, Zicker F, (1996) The reemergence of visceral leishmaniais in Brazil. Emerg Infect Dis 2: 145-146.
4. Faucher B, Piarroux R, (2011) Visceral leishmaniasis: an update. Rev Med Interne 32: 544-551.
5. Harhay MO, Olliaro PL, Costa DL, Costa CH, (2011) Urban parasitology: visceral leishmaniasis in Brazil. Trends Parasitol 27: 403-409.
6. Maia-Elkhoury NA, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA, (2008) Visceral leishmaniasis in Brazil: trends and challenges. Cad Saude Publica 24: 2941-2947.
7. Andrade HM, Toledo VP, Pinheiro MB, Guimarães TM, Oliveira NC, et al. (2011) Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (= L. chagasi) in Brazil. Vet Parasitol 181: 83-90.
8. Noli C, Auxilia ST, (2005) Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16: 213-232.
9. Oliveira CD, Moarais MH, Machado-Coelho GL, (2008) Visceral leishmaniasis in large Brazilian cities: challenges for control. Cad Saude Publica 24: 2953-2958.
10. Silva SM, Amorim IF, Ribeiro RR, Azevedo EG, Demicheli C, et al. (2012) Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis. Antimicrob Agents Chemother 56: 2858-2867.
11. Ashford DA, David JR, Freire M, David R, Sherlock I, et al. (1998) Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 59: 53-57.
12. Costa CH, (2011) How effective is dog culling in controlling zoonotic visceral leishmaniasis? A critical evaluation of the science, politics and ethics behind this public health policy. Rev Soc Bras Med Trop 44: 232-242.
13. Guarga JL, Moreno J, Lucientes J, Gracia MJ, Peribáñez MA, et al. (2002) Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol 88: 13-20.
14. Jamshidi Sh, Avizeh R, Mohebali M, Bokaie S, (2011) Immunotherapy using autoclaved L. major antigens and M. vaccae with meglumine antimoniate for the treatment of experimental canine visceral leishmaniasis. Iranian J Parasitol 6: 26-34.
15. Neogy AB, Vouldoukis I, Costa JM, Monjour L, (1994) Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Vet Parasitol 54: 367-373.
16. Miret J, Nascimento E, Sampaio W, França JC, Fujiwara RT, et al. (2008) Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26: 1585-1594.
17. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, et al. (2010) Treatment of canine visceral leishmaniasis by the vaccine Leish-111f + MPL-SE. Vaccine 28: 3333-3340.
18. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza W, Okada LYH, Trivellato FAA, et al. (2004) Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22: 2234-2243.
19. Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FAA, Kawasaki JKA, et al. (2010) Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine 28: 597-603.
20. Santos FN, Borja-Cabrera GP, Miyashiro LM, Grechi J, Reis AB, et al. (2007) Immunotherapy against canine visceral leishmaniasis with the saponin enriched Leishmune vaccine. Vaccine 25: 6176-6190.
21. Dias SS, Pinheiro PHC, Katz S, Santos MRM, Barbiéri CL, (2005) A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American Visceral Leishmaniasis. Am J Trop Med Hyg 72: 126-132.
22. Pinheiro PHC, Dias SS, Eulálio KD, Mendonça IL, Katz S, Barbiéri CL, (2005) Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses. Infect Immun 73: 3787-3789.
23. Pinheiro PHC, Pinheiro AN, Ferreira JHL, Costa FAL, Katz S, Barbiéri CL, (2009) A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi as an antigen for delayed-type hypersensitivity assays and serodiagnosis of canine visceral leishmaniasis. Vet Parasitol 162: 32-39.
24. Ferreira JHL, Gentil LG, Dias SS, Fedeli CEC, Katz S, Barbiéri CL, (2008) Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis. Vaccine 26: 677-685.
25. Matsui K, Yoshimoto T, Tsutsui H, Hyodo Y, Hayashi N, et al. (1997) Propionibacterium acnes treatment diminishes CD4+NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 159: 97-106.
26. Tsutsui H, Matsui K, Kawada N, Hyodo Y, Hayashi N, et al. (1997) IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 159: 3961-3967.
27. Pinto AR, Beyrodt CGP, Lopes RAM, Barbiéri CL, (2000) Identification of a 30 kDa antigen from Leishmania (L.) chagasi amastigotes implicated in protective cellular responses in a murine model. Int J Parasitol 30: 599-607.
28. Drumond KO, Costa FA, (2011) Forty years of visceral leishmaniasis in the State of Piaui: a review. Rev Inst Med Trop São Paulo 53: 3-11.
29. Barbiéri CL, Doine AI, Freymüller E, (1990) Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp Parasitol 71: 218-228.
30. Sheffield P, Garrard S, Derewenda Z, (1999) Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Prot Expres Purif 15: 34-39.
31. Skeiky YAW, Coler RN, Brannon M, Stromberg E, Greeson K, et al. (2002) Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20: 3292-3303.
32. Beyrodt CGP, Pinto AR, Freymüller E, Barbiéri CL, (1997) Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infect Immun 65: 2052-2059.
33. Mussalem JS, Squaiella-Baptistão CC, Teixeira D, Yendo TM, Thies FG, et al. (2012) Adjuvant effect of killed Propionibacterium acnes on mouse peritoneal B-1 lymphocytes and their early phagocyte differentiation. PLoS ONE 7: e33955 doi:10.1371/journal.pone.0033955.
34. Bradford MM, (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
35. Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F, (1995) Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39: 2167-2168.
36. Maltezou HC, (2008) Visceral leishmaniasis: advances in treatment. Recent Pat Antiinfect Drug Discov 3: 192-198.
37. Musa AM, Noazin S, Khalil EAG, Modabber F, (2010) Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans R Soc Trop Med Hyg 104: 1-2.
38. Deplazes P, Smith NC, Arnold P, Lutz H, Eckert J, (1995) Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 17: 451-458.
39. Bergeron LM, McCandless EE, Dunham S, Dunkle B, Zhu Y, et al. (2014) Comparative functional characterization of canine IgG subclasses. Vet Immunol Immunopathol 157: 31-41.
40. Nieto CG, Garcia-Alonso M, Requena JM, Miron C, Soto M, et al. (1999) Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet Immunol Immunopathol 67: 117-130.
41. Fernandes AP, Costa MMS, Coelho EAF, Michalick MSM, Freitas E, et al. (2008) Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26: 5888-5895.
42. Pinelli E, Killick-Kendrick R, Wagenaar J, Bernardina W, Del Real G, Ruitenberg J, (1994) Cellular and humoral responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62: 229-235.
43. Pinelli E, van der Kaaij SY, Slappendel R, Fragio C, Ruitenberg EJ, et al. (1999) Detection of canine cytokine gene expression by reverse transcription-polymerase chain reaction. Vet Immunol Immunopathol 69: 121-126.
44. Vouldoukis I, Drapier JC, Nüssler AK, Tselentis Y, Silva OA, et al. (1996) Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 40: 253-256.
45. Panaro MA, Acquafredda A, Lisi S, Lofrumento DD, Mitolo V, et al. (2001) Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis 24: 187-195.
46. Lage RS, Oliveira GC, Busek SU, Guerra LL, Giunchetti RC, et al. (2007) Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet Immunol Immunopathol 115: 135-145.
47. Manna L, Reale S, Viola E, Vitale F, Manzillo VF, et al. (2006) Leishmania DNA load and cytokine expression levels in asymptomatic naturally infected dogs. Vet Parasitol 142: 271-280.
48. Mussalem JS, Vasconcelos JR, Squaiella CC, Ananias RZ, Braga EG, et al. (2006) Adjuvant effect of the Propionibacterium acnes and its purified soluble polysaccharide on the immunization with plasmidial DNA containing a Trypanosoma cruzi gene. Microbiol Immunol 50: 253-263.
49. Hill JO, (1987) Modulation of the pattern of development of experimental disseminated leishmaniasis by Corynebacterium parvum. J Leukoc Biol 41: 165-167.
50. Ghosh A, Zhang WW, Matlashewski G, (2001) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20: 59-66.
51. Pinelli E, Gonzalo RM, Boog CJP, Rutten VPMG, Gebhard D, et al. (1995) Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol 25: 1594-1600.
52. Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Giunchetti RC, Carneiro CM, et al. (2009) Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet Immunol Immunopathol 128: 87-95.